Four distinct immune pathways — adaptive T-cell modulation, gut-immune axis repair, innate antimicrobial defense, and neuroinflammatory suppression — each requiring a different compound. This guide covers the mechanisms, evidence, and stacking protocols for Thymosin Alpha-1, BPC-157, LL-37, and VIP.
Research context only. All compounds on this page are research chemicals. None are FDA-approved for the immune indications discussed. Thymosin Alpha-1 (Zadaxin) is approved in 35+ countries but not the US. Always consult a qualified physician before use.
Promotes T-cell maturation in the thymus, enhances Th1 cytokine production (IL-2, IFN-γ), activates dendritic cells, and restores immune balance in immunocompromised states. The most clinically validated immune peptide.
Repairs intestinal epithelial integrity, reduces gut permeability, and suppresses NF-κB-mediated inflammation. ~70% of immune tissue is gut-associated; BPC-157 targets this interface directly.
The only human cathelicidin AMP — disrupts bacterial cell membranes, promotes neutrophil recruitment, modulates TLR4 endotoxin responses, and enhances wound healing. First-line innate immune defense.
Suppresses TNF-α, IL-6, IL-12 via VPAC1/VPAC2 signaling, promotes regulatory T-cell differentiation, and modulates the gut-brain immune axis. Most relevant for neuroinflammatory immune dysregulation.
| Compound | Immune Mechanism | Primary Benefit | Dose (Research) | Evidence Level |
|---|---|---|---|---|
| Thymosin Alpha-1 | Thymic T-cell maturation, Th1/Th2 balance, dendritic cell activation | Adaptive immunity restoration, antiviral T-cell enhancement | 1.6 mg SubQ, 2×/week (standard protocol) | Strong (human trials) |
| BPC-157 | Gut-immune axis repair, NF-κB inhibition, NO pathway modulation | Gut permeability reduction, systemic inflammation suppression | 250–500 mcg SubQ or oral, daily | Strong (preclinical) |
| LL-37 | Cathelicidin AMP — bacterial membrane disruption, TLR4 modulation | Innate antimicrobial defense, wound healing, neutrophil recruitment | 1–5 mg SubQ, 3×/week (research protocols) | Moderate (preclinical + early human) |
| VIP | VPAC1/VPAC2 agonism → TNF-α/IL-6 suppression, Treg promotion | Neuroinflammation reduction, autoimmune cytokine suppression | 50–100 mcg SubQ or intranasal, daily | Moderate (preclinical + Phase 2) |
28-amino acid thymic peptide · Approved in 35+ countries
Tα1 promotes T-cell maturation in the thymus by activating thymosin receptors on T-cell precursors, driving differentiation into CD4+ helper and CD8+ cytotoxic T-cells. It enhances Th1 cytokine production (IL-2, IFN-γ), activates dendritic cells via TLR9 signaling, upregulates MHC class I expression on tumor and virally infected cells, and promotes NK cell cytotoxicity. In immunocompromised states, Tα1 restores the Th1/Th2 balance that chronic illness and aging shift toward Th2 dominance.
Tα1 (Zadaxin) is approved in 35+ countries for chronic hepatitis B and C, where it enhances antiviral T-cell responses. Phase 3 trials showed significant improvements in HBeAg seroconversion rates. In COVID-19, a Chinese Phase 3 trial (n=361) showed Tα1 reduced 28-day mortality in severe cases by 30% vs standard care. Multiple Phase 2 trials support its use as a cancer immunotherapy adjuvant, enhancing responses to checkpoint inhibitors and vaccines.
Body Protection Compound · 15-amino acid gastric pentadecapeptide
BPC-157 supports immunity primarily through the gut-immune axis: it repairs intestinal epithelial tight junctions, reducing gut permeability and the systemic antigen load that drives chronic immune activation. It suppresses NF-κB signaling — the master regulator of pro-inflammatory cytokine production — and modulates nitric oxide synthase (NOS) activity, which affects macrophage polarization and inflammatory resolution. In animal models, BPC-157 has shown protective effects against endotoxin-induced systemic inflammation and sepsis-like states.
Approximately 70% of the immune system is housed in gut-associated lymphoid tissue (GALT) — Peyer's patches, mesenteric lymph nodes, and intraepithelial lymphocytes. When gut permeability increases, bacterial LPS and undigested food antigens enter systemic circulation, triggering chronic low-grade immune activation. BPC-157 (oral route) directly targets this interface, making it uniquely relevant for immune conditions driven by gut dysbiosis, IBD, or post-antibiotic microbiome disruption.
37-amino acid antimicrobial peptide · Only human cathelicidin
LL-37 disrupts bacterial cell membranes through electrostatic interaction with anionic phospholipids, forming transmembrane pores that cause bacterial lysis. It is effective against gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses. Beyond direct antimicrobial action, LL-37 promotes neutrophil and monocyte recruitment, enhances phagocytosis, and modulates TLR4 responses to prevent excessive endotoxin-driven inflammation — a dual role as both attacker and regulator of innate immunity.
LL-37 promotes dendritic cell maturation, enhancing antigen presentation to T-cells and bridging innate and adaptive immunity. It also has direct wound healing effects: it promotes keratinocyte migration, angiogenesis, and fibroblast activation. Low LL-37 levels are associated with increased susceptibility to bacterial infections, atopic dermatitis, and inflammatory bowel disease. LL-37 deficiency is a key mechanism in the increased infection susceptibility seen in vitamin D deficiency, as vitamin D upregulates cathelicidin expression.
28-amino acid neuropeptide · VPAC1/VPAC2 receptor agonist
VIP acts through VPAC1 and VPAC2 receptors expressed on T-cells, macrophages, dendritic cells, and mast cells. Receptor activation increases intracellular cAMP, which suppresses NF-κB and MAPK signaling — reducing TNF-α, IL-6, IL-12, and IFN-γ production. Simultaneously, VIP promotes IL-10 (anti-inflammatory) and TGF-β (regulatory) cytokine production, and drives regulatory T-cell (Treg) differentiation from naive CD4+ T-cells. This dual suppression/promotion profile makes VIP uniquely effective for autoimmune and neuroinflammatory conditions.
VIP is produced by neurons in the enteric nervous system and acts as a key mediator of the gut-brain immune axis. It regulates intestinal motility, mucosal immunity, and gut microbiome composition. In the central nervous system, VIP suppresses microglial activation and neuroinflammation — making it relevant for conditions like chronic fatigue syndrome, post-viral neuroinflammation, and autoimmune neurological conditions. Phase 2 trials have studied VIP for rheumatoid arthritis and IBD, showing significant reductions in inflammatory markers.
Post-viral recovery, chronic immune suppression, vaccine response optimization
| Compound | Dose | Timing |
|---|---|---|
| Thymosin Alpha-1 | 1.6 mg SubQ | 2× per week (Mon/Thu) |
| BPC-157 | 500 mcg SubQ | Daily, morning |
Thymosin Alpha-1 drives T-cell maturation and Th1 cytokine production; BPC-157 repairs the gut-immune axis and reduces systemic inflammatory burden. This combination addresses both adaptive immune capacity and the gut permeability that drives chronic immune activation.
Acute infection recovery, post-antibiotic immune rebuilding, recurrent infections
| Compound | Dose | Timing |
|---|---|---|
| Thymosin Alpha-1 | 1.6 mg SubQ | 2× per week |
| LL-37 | 2 mg SubQ | 3× per week |
| BPC-157 | 250 mcg oral | Daily, with food |
LL-37 provides direct innate antimicrobial defense and promotes neutrophil recruitment; Thymosin Alpha-1 rebuilds adaptive T-cell responses; BPC-157 (oral) targets gut-associated lymphoid tissue repair. This stack is most relevant for post-infection or post-antibiotic immune rebuilding.
Chronic fatigue, autoimmune neurological conditions, post-viral neuroinflammation
| Compound | Dose | Timing |
|---|---|---|
| VIP | 50 mcg SubQ or intranasal | Daily |
| BPC-157 | 500 mcg SubQ | Daily |
| Thymosin Alpha-1 | 1.6 mg SubQ | 2× per week |
VIP suppresses central neuroinflammatory cytokines (TNF-α, IL-6) and promotes regulatory T-cell differentiation; BPC-157 addresses gut-brain axis inflammation; Thymosin Alpha-1 restores systemic immune balance. This combination is most relevant for conditions where neuroinflammation drives immune dysregulation.
| Immune Goal | Primary Compound | Add-On |
|---|---|---|
| Post-viral recovery / long COVID immune rebuilding | Thymosin Alpha-1 | BPC-157 (oral) |
| Recurrent bacterial infections / low innate immunity | LL-37 | Thymosin Alpha-1 |
| Gut permeability / leaky gut driving immune activation | BPC-157 (oral) | Thymosin Alpha-1 |
| Neuroinflammation / chronic fatigue / autoimmune flares | VIP | BPC-157 |
| Vaccine response optimization / immunosenescence | Thymosin Alpha-1 | None required |
| Wound healing with immune support | LL-37 | BPC-157 |
| Inflammatory bowel disease / gut autoimmunity | VIP | BPC-157 (oral) |
| Cancer immunotherapy adjuvant (research context) | Thymosin Alpha-1 | None required |
The most researched peptides for immune support are Thymosin Alpha-1 (thymic T-cell maturation and Th1/Th2 balance), BPC-157 (gut-immune axis repair and NF-κB inhibition), LL-37 (innate immune defense — antimicrobial peptide), and VIP (anti-inflammatory neuropeptide for neuroinflammatory immune dysregulation). Each targets a distinct immune pathway: Thymosin Alpha-1 modulates adaptive immunity; BPC-157 repairs the gut-immune interface; LL-37 provides direct antimicrobial defense; VIP suppresses pro-inflammatory cytokine cascades.
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide derived from the thymus gland that promotes T-cell maturation, enhances Th1 cytokine production (IL-2, IFN-γ), and restores immune balance in immunocompromised states. It has been used clinically in over 35 countries for hepatitis B, hepatitis C, and as an adjuvant to cancer immunotherapy. Tα1 activates dendritic cells, upregulates MHC class I expression, and has been studied in sepsis and COVID-19 for its ability to reduce inflammatory cytokine storms while simultaneously boosting antiviral T-cell responses.
BPC-157 supports immune function primarily through the gut-immune axis: approximately 70% of the immune system is housed in gut-associated lymphoid tissue (GALT), and BPC-157's ability to repair intestinal epithelial integrity, reduce gut permeability ('leaky gut'), and suppress NF-κB-mediated inflammation directly reduces systemic immune burden. BPC-157 also modulates nitric oxide signaling, which affects macrophage activation and inflammatory cytokine production. In animal models, BPC-157 has shown protective effects against endotoxin-induced systemic inflammation and sepsis-like states.
LL-37 is the only human cathelicidin antimicrobial peptide (AMP) — a 37-amino acid innate immune peptide produced by neutrophils, macrophages, and epithelial cells. It provides direct antimicrobial defense by disrupting bacterial cell membranes, and it also modulates adaptive immunity by promoting dendritic cell maturation, enhancing neutrophil recruitment, and suppressing excessive TLR4-mediated endotoxin responses. LL-37 has been studied for wound healing, respiratory infections, and inflammatory bowel disease. Low LL-37 levels are associated with increased susceptibility to bacterial infections and autoimmune conditions.
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that acts as a potent anti-inflammatory agent through VPAC1/VPAC2 receptor signaling. VIP suppresses TNF-α, IL-6, IL-12, and IFN-γ production in macrophages and T-cells, while promoting IL-10 (anti-inflammatory) and regulatory T-cell (Treg) differentiation. It has been studied for rheumatoid arthritis, inflammatory bowel disease, and sepsis. VIP also modulates the gut-brain axis and has neuroprotective effects relevant to neuroinflammatory conditions. Its dual role as both a neuropeptide and immune modulator makes it unique among research peptides.
Several research peptides show potential for autoimmune modulation. Thymosin Alpha-1 restores Th1/Th2 balance and promotes regulatory T-cell activity, which may reduce autoimmune flares. VIP promotes Treg differentiation and suppresses pro-inflammatory cytokines implicated in rheumatoid arthritis, lupus, and IBD. BPC-157 reduces gut permeability, which is a key driver of autoimmune activation in conditions like Hashimoto's thyroiditis and celiac disease. LL-37 has a complex role — it can both suppress excessive TLR4 responses and, in some contexts, trigger autoimmune reactions (as seen in psoriasis). These are research compounds; no peptide is FDA-approved for autoimmune disease.
The most commonly researched immune support stack combines Thymosin Alpha-1 (adaptive immune modulation, T-cell maturation) with BPC-157 (gut-immune axis repair, NF-κB suppression). For acute infections or post-viral recovery, LL-37 can be added for innate immune defense. For neuroinflammatory immune dysregulation (chronic fatigue, autoimmune neurological conditions), VIP is added to suppress central inflammatory signaling. Thymosin Alpha-1 and BPC-157 are generally considered safe to stack; LL-37 and VIP are typically used in shorter, targeted cycles.
Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries for hepatitis B, hepatitis C, and as a vaccine adjuvant, but it is not FDA-approved in the United States. It has been studied in multiple Phase 2 and Phase 3 clinical trials. In the US, it is available as a research chemical and has been used off-label by some physicians for immune support, cancer adjuvant therapy, and post-viral recovery. The FDA has granted Orphan Drug Designation for Tα1 in certain indications. Researchers should be aware of the regulatory status in their jurisdiction.
Purgo Labs offers ≥99% purity, third-party COA-verified Thymosin Alpha-1, BPC-157, and LL-37 for research purposes.
Shop Immune Peptides at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.